Literature DB >> 9491321

Mapping of a new target region of allelic loss to a 2-cM interval at 22q13.1 in primary breast cancer.

A Iida1, K Kurose, R Isobe, F Akiyama, G Sakamoto, M Yoshimoto, F Kasumi, Y Nakamura, M Emi.   

Abstract

Allelic losses on chromosome arm 22q are frequently observed in human meningiomas and in carcinomas of the colon, ovary, and breast. Among 140 primary breast cancers we examined for loss of heterozygosity (LOH) at 16 polymorphic loci on the long arm of chromosome 22, 56 (40%) showed LOH for at least one locus. Eleven of these tumors had retained heterozygosity for markers proximal to the NF2 locus but showed LOH for markers distal to NF2. Deletion mapping indicated a new common region of deletion, 2-cM in extent, at q13.1 between Interleukin 2 receptor beta (IL2RB) and D22S279. Our results raise the possibility that one or more tumor suppressor genes associated with breast cancer may exist at 22q13.1. Comparison of these results with clinicohistological data indicated that allelic losses on 22q tend to occur more frequently in tumors of malignant histological types.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9491321

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  15 in total

Review 1.  The bisecting GlcNAc in cell growth control and tumor progression.

Authors:  Hazuki E Miwa; Yinghui Song; Richard Alvarez; Richard D Cummings; Pamela Stanley
Journal:  Glycoconj J       Date:  2012-04-04       Impact factor: 2.916

2.  The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer.

Authors:  Heba Allam; Blake P Johnson; Mao Zhang; Zhongpeng Lu; Martin J Cannon; Karen L Abbott
Journal:  J Biol Chem       Date:  2017-08-23       Impact factor: 5.157

3.  Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA2 gene on chromosome 22q13.1.

Authors:  Z Ma; X Wang; W Nowatzke; S Ramanadham; J Turk
Journal:  J Biol Chem       Date:  1999-04-02       Impact factor: 5.157

4.  The bisecting GlcNAc on N-glycans inhibits growth factor signaling and retards mammary tumor progression.

Authors:  Yinghui Song; Jason A Aglipay; Joshua D Bernstein; Sumanta Goswami; Pamela Stanley
Journal:  Cancer Res       Date:  2010-04-15       Impact factor: 12.701

5.  Detailed deletion mapping of loss of heterozygosity on 22q13 in sporadic colorectal cancer.

Authors:  Hai-Tao Zheng; Zhi-Hai Peng; Chong-Zhi Zhou; Da-Peng Li; Zhao-Wen Wang; Guo-Qiang Qiu; Lin He
Journal:  World J Gastroenterol       Date:  2005-03-21       Impact factor: 5.742

6.  Topographical distributions of allelic loss in individual non-small-cell lung cancers.

Authors:  Y Yatabe; H Konishi; T Mitsudomi; S Nakamura; T Takahashi
Journal:  Am J Pathol       Date:  2000-09       Impact factor: 4.307

7.  Loss of heterozygosity on long arm of chromosome 22 in sporadic colorectal carcinoma.

Authors:  Chong-Zhi Zhou; Zhi-Hai Peng; Fang Zhang; Guo-Qiang Qiu; Lin He
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

Review 8.  Regulation of PI3K effector signalling in cancer by the phosphoinositide phosphatases.

Authors:  Samuel J Rodgers; Daniel T Ferguson; Christina A Mitchell; Lisa M Ooms
Journal:  Biosci Rep       Date:  2017-02-10       Impact factor: 3.840

9.  Genomic and phenotypic profiles of two Brazilian breast cancer cell lines derived from primary human tumors.

Authors:  Natássia C R Corrêa; Hellen Kuasne; Jerusa A Q A Faria; Ciça C S Seixas; Iria G D Santos; Francine B Abreu; Suely Nonogaki; Rafael M Rocha; Gerluza Aparecida Borges Silva; Helenice Gobbi; Silvia R Rogatto; Alfredo M Goes; Dawidson A Gomes
Journal:  Oncol Rep       Date:  2013-02-12       Impact factor: 3.906

10.  No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer.

Authors:  Ian G Campbell; David Choong; Georgia Chenevix-Trench
Journal:  Breast Cancer Res       Date:  2004-05-14       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.